Ozempic Gastroparesis Settlement: Legal Options for Massachusetts Patients

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Surveillance to Targeted Drug Safety Analysis

The legacy domain has established a foundation in general health and science information, drawing on structured public data sources such as ClinicalTrials.gov, PubMed, and FDA databases. This heritage provides a reliable framework for analyzing clinical trial outcomes, drug safety profiles, and regulatory updates across a broad spectrum of therapeutic areas. The focus has been on delivering neutral, evidence-based summaries that serve researchers and healthcare professionals seeking to understand emerging medical data. Within this context, the domain’s analytical capabilities can be directed toward a specific area of growing public and legal interest: the relationship between GLP-1 receptor agonist exposure and gastrointestinal motility disorders. The drug Ozempic, widely prescribed for type 2 diabetes and weight management, has been associated with reports of gastroparesis—a condition characterized by delayed gastric emptying. This intersection of pharmacovigilance data and patient safety concerns has led to legal proceedings, including the Ozempic Gastroparesis Settlement in Massachusetts. Transitioning from general health surveillance to this targeted concern, the domain can now address the occupational exposure question: how might individuals with prolonged or high-dose exposure to Ozempic assess their risk of developing gastroparesis-related complications? This pivot maintains the academic tone while shifting focus from broad clinical data to a specific, actionable inquiry for affected populations.

Find Out If You Qualify for Compensation →

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, electrolyte imbalances, and impaired quality of life. While gastroparesis has multiple etiologies, including diabetes itself, drug-induced cases are increasingly recognized. Ozempic (semaglutide) works by mimicking the action of the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This latter effect is integral to its therapeutic action but can become pathological. The drug's prescribing information documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% for the 0.5 mg dose and 36.4% for the 1 mg dose, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation rates due to gastrointestinal adverse reactions were 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis, the symptoms overlap significantly, and the drug's known effect on gastric motility provides a mechanistic basis.

Mechanistic Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's action on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. In susceptible individuals, this pharmacodynamic effect may become excessive, leading to clinically significant gastroparesis. The risk may be heightened in patients with pre-existing autonomic neuropathy, a common complication of diabetes, which itself can impair gastric motility. The timeline between exposure and documented harm varies; symptoms often emerge during dose escalation, as noted in clinical trials, but cases of persistent gastroparesis after drug initiation have been reported in postmarketing surveillance. Regarding the adequacy of warnings, the Ozempic prescribing information includes a section on gastrointestinal adverse reactions but does not specifically mention gastroparesis as a distinct warning or caution. The label does address serious hypersensitivity reactions, including anaphylaxis and angioedema, and acute gallbladder disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of explicit language about gastroparesis may leave patients and healthcare providers unaware of this potential complication. This gap in risk communication is a central issue in settlement considerations for affected patients in Massachusetts.

Legal Context: Ozempic Gastroparesis Settlement in Massachusetts

For patients who develop gastroparesis after using Ozempic, settlement-related considerations include the need to establish a causal link between the drug and the injury. Key factors include the temporal relationship between drug initiation and symptom onset, exclusion of other causes, and documentation of diagnostic testing. The timeline between exposure and harm is critical; cases where symptoms began during dose escalation or shortly after starting the drug may support a stronger claim. Patients should retain medical records, including prescription histories, symptom diaries, and gastric emptying study results. In Massachusetts, legal claims related to Ozempic-induced gastroparesis may fall under product liability law, alleging inadequate warnings or design defects. Settlement negotiations often consider the severity of the injury, medical expenses, lost wages, and pain and suffering. Given the growing number of reports, some cases may be consolidated into multidistrict litigation, though individual settlements remain possible. In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, and its pharmacological effect on gastric emptying provides a plausible mechanism for gastroparesis. The current labeling does not explicitly warn about this risk, which may be a factor in legal claims. Affected patients in Massachusetts should seek legal counsel to evaluate their options, particularly if they experienced symptoms during dose escalation and have documented evidence of gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the Ozempic Gastroparesis Settlement in Massachusetts?

The Ozempic Gastroparesis Settlement refers to legal claims in Massachusetts where patients allege that Ozempic (semaglutide) caused gastroparesis, a condition of delayed gastric emptying. These claims often focus on inadequate warnings about gastrointestinal risks. Affected individuals may seek compensation for medical expenses, lost wages, and pain and suffering. Each case is evaluated based on the strength of the causal link between Ozempic use and the injury.

How can I prove my gastroparesis is linked to Ozempic?

To establish a link, you need a documented diagnosis of gastroparesis via gastric emptying scintigraphy, a clear temporal relationship between starting Ozempic and symptom onset (often during dose escalation), and exclusion of other causes such as diabetic gastroparesis or mechanical obstruction. Retaining medical records, prescription history, and symptom diaries is crucial. Consulting a Massachusetts product liability attorney can help evaluate your case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.